Status:
COMPLETED
Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study was designed to test safety aspects and effects on lung function of a new dry powder version of GSK159797 for asthmatic subjects to inhale. This will allow comparison with previous studies ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Subjects with mild to moderate stable asthma but no other lung problems.
- Male subjects or females who are not able to get pregnant (e.g. post-menopausal or surgically sterile).
- Non-smokers.
- Subjects that show a measurable improvement in the function of their lungs after a single dose of salbutamol.
- Exclusion criteria:
- Any significant illness.
- Subjects with heart problems.
- Subjects who have had a cold or chest infection 2-4 weeks prior to the study.
- Subjects who take medication for their asthma, or other conditions, not compatible with the study.
Exclusion
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2004
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00354666
Start Date
September 1 2004
End Date
December 1 2004
Last Update
September 1 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.